Executive Committee
The Executive Committee will be responsible for general oversight of the consortium. Oversight activities include fostering adherence to the consortium’s mission and guiding principles, determining each workgroup’s project funding, approving new members, and serving as the public face of the consortium. The committee consists of 17 total seats, with three seats each assigned to representatives from industry, oncologists/specialists, payers, primary care/prevention, and public/patient advocacy.
Meet the Executive Committee Leadership
-
Michelle Le Beau, Ph.D
Chair
Chief Science Officer
Cancer Prevention and Research Institute of Texas -
Larry Kessler, ScD
Deputy Chair
Professor, Health Systems and Population Health
University of Washington
Meet the Executive Committee Membership
-
Julian Adams, PhD
Chief Science Officer
Stand Up To Cancer -
Tomasz Beer, MD
Vice President and Chief Medical Officer for Multi-Cancer Early Detection
Exact Sciences -
David Crosby
Head of Prevention and Early Detection Research
Cancer Research UK -
William L. Dahut, MD
Chief Scientific Officer
American Cancer Society -
Anne-Renee Hartman
Co-founder and Chief Medical Officer
Adela -
Sam Janes
Professor of Respiratory Medicine
University College London -
Eric A. Klein, MD
Distinguished Scientist
GRAIL -
Blase Polite
Executive Medical Director
Cancer Accountable Care at the University of Chicago -
Tim Rebbeck
Vincent L. Gregory Professor of Cancer Prevention
Dana-Farber Cancer Institute -
Richard Roope, MA, MBBS, MSc
Rapid Investigation Service GP
-
Fiona Walter
Director
Wolfson Institute of Population Health -
Robert Winn, MD
Director
VCU Massey Cancer Center
Meet the Executive Committee Advisors
-
Jeff Allen
President & Chief Executive Officer
Friends of Cancer Research -
Billy Boyle
Chief Executive Officer
Owlstone -
Brian Druker, MD
Director
OHSU Knight Cancer Institute -
Lecia Sequist, MD, MPH
Director
Center for Innovation in Early Cancer Detection